Aldoxorubicin Improves Outcomes in Relapsed/Refractory Sarcoma
Aldoxorubicin significantly prolongs PFS and provides better objective response rates than investigators’ choice of treatment or standard of care in the treatment of soft tissue sarcoma.
ASCO 2017
Promising Activity Reported for Nivolumab in Gynecologic Cancers
Nivolumab, a programmed death (PD)-1 inhibitor, showed promising clinical activity in recurrent or metastatic cervical cancers and provides a promising new approach to treatment.
Sarcoma: Next-generation Sequencing Has Implications for Diagnosis and Treatment
A retrospective analysis of next-generation sequencing profiles has diagnostic and therapeutic implications for patients with soft-tissue or bone sarcoma.
Personalizing Care for Patients With Sarcoma
The landscape of complex genetic mutations in sarcomas seen through next-generation sequence profiling provides a rationale for a study to match patients to the appropriate therapy.
Endometrial Cancer: Adjuvant Taxane Plus Platinum Agent Does Not Improve Outcomes
A study concluded that adjuvant therapy with a taxane and a platinum agent was not superior over standard therapy for women with high-risk endometrial cancer.
Pembrolizumab Active in Few Soft Tissue, Bone Sarcoma Subtypes
Pembrolizumab shows antitumor activity in osteosarcoma and undifferentiated pleomorphic sarcoma, but not other types of soft tissue sarcomas.
Cabozantinib Evaluated in Aggressive Endometrial Cancer Subtype
Cabozantinib may have activity in carcinosarcoma and warrants further investigation.
Do Specialized Cancer Centers Improve Outcomes for Patients With Ewing Sarcoma?
Patients with Ewing sarcoma aged 19 to 39 years may benefit from treatment at a specialized cancer center.
Young Patients With CLL At Risk for Secondary Cancers
Patients with chronic lymphocytic leukemia younger than age 55 are at an increased risk for multiple types of secondary cancers for up to 15 years after diagnosis.
Ibrutinib Provides Long-term Benefits for Patients With CLL
Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia regardless of cytogenetic risk factors.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2017
